ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results

Anagnostou, V; Ho, CRY; Nicholas, G; Juergens, RA; Sacher, A; Fung, AS; Wheatley-Price, P; Laurie, SA; Levy, B; Brahmer, JR; Balan, A; Niknafs, N; Avrutin, E; Zhu, LT; Sausen, M; Bradbury, PA; O'Donnell-Tormey, J; Gaudreau, PO; Ding, KY; Dancey, J

Anagnostou, V (通讯作者)，Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD 21218 USA.;Anagnostou, V (通讯作者)，Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Sch Med, Baltimore, MD 21218 USA.;Dancey, J (通讯作者)，Queens Univ, Canadian Canc Trials Grp, Kingston, ON, Canada.

NATURE MEDICINE, 2023; 29 (10): 2559

Abstract

Circulating tumor DNA (ctDNA) has shown promise in capturing primary resistance to immunotherapy. BR.36 is a multi-center, randomized, ctDNA-directed,......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索